Proscia, Ibex, and Quest Diagnostics Webinar: Quantifying the Value of AI-Powered Digital WorkflowsSIGN UP

The new era of drug development is powered by digital pathology

Precision medicine strategies rooted in histology now dominate therapeutic pipelines, with next-generation therapies requiring precise, tissue-based digital diagnostics. At the core of this shift is computational pathology, emerging at the forefront of AI-driven strategies to accelerate programs from discovery to commercialization.

To fully harness digital pathology’s transformative potential, life sciences R&D teams need advanced solutions designed to drive innovation at every stage.

Revolutionary advancements in technology and science have elevated digital pathology’s role in drug development.

Advancing novel therapies from discovery to diagnostics

Leading life sciences organizations leverage Proscia’s enterprise pathology platform, real-world data, and AI solutions across the R&D lifecycle to bring treatments to market faster and reach more patients worldwide.

Driving breakthroughs across the life sciences industry

Drug discovery and development teams partner with Proscia to speed up scientific progress, enhance collaboration across teams and partners, and ultimately deliver life-saving therapies and diagnostics to patients faster.


Proscia’s solutions advancing therapeutic R&D

With products that uniquely bridge the healthcare and life sciences ecosystems, Proscia empowers R&D teams with clinically relevant data to fuel the discovery of novel therapies, diagnostics, and AI-based biomarkers, and enables these innovations to reach more patients.

The solutions driving these advancements in life sciences include our enterprise pathology platform, real-world data, and AI offerings.

Concentriq platform

Concentriq LS is the enterprise pathology platform for life sciences that serves as the central hub for AI-enabled scientific workflows, unifying data, teams, and applications to power image-based research from discovery to early clinical development.

The Concentriq AP-Dx platform, which features regulated components for diagnostic use, advances late-stage clinical trials and provides an accelerated pathway to deployment of novel diagnostics and therapies through Proscia’s global lab network.

Real-world data

Leverage one of the world’s largest pathology databases to access highly relevant RWD cohorts for scientific discovery and pharmaceutical development.

Derived from a diverse repository of whole slide images enhanced with structured clinical and genomic data, these actionable cohorts are seamlessly delivered to the Concentriq platform where they can be instantly incorporated into existing studies and used to develop proprietary AI models.

AI solutions

Run leading AI applications with image analysis workflows to optimize quality control, toxicity assessments, patient stratification, and more.

Develop high-performing AI models 13x faster with Concentriq Embeddings by seamlessly transforming large datasets into AI-ready representations using state-of-the-art foundation models directly within the Concentriq platform.

On-Demand Webinar

Transforming precision programs with pathology RWD

Leaders from Genentech and PathGroup discuss how the digitization of pathology has generated a wealth of untapped data that is driving the next breakthroughs in precision medicine drug discovery and development. Watch the webinar and learn about:

  • The value of RWD in accelerating critical milestones
  • The future impact of RWD on precision medicine as digital pathology adoption continues to rise
  • The role clinical laboratories play in advancing the novel diagnostics and therapies of tomorrow

Watch On-Demand

From Bedside to Bench and Back: How Digital Pathology is Fueling Precision Medicine with Unprecedented Real-World Data

Build more AI models, faster with Concentriq

With Concentriq Embeddings—Proscia’s pathology foundation model API—data science and AI teams within life sciences organizations are rapidly building high-performing AI algorithms at scale to advance precision medicine portfolios.

Discover how Proscia’s AI R&D team leveraged Concentriq Embeddings to build 80 breast cancer biomarker prediction models in under 24 hours.

READ THE CASE STUDY

14 of the top 20 Pharma leaders run Concentriq

Bristol Myers Squibb Logo

“Proscia’s Concentriq Platform is helping us drive value. We can combine all of our different image analyses under one roof, which I thought was a huge benefit. You can start to establish a common practice within images or pathology data.”

Principal Scientist

Discover how Proscia can accelerate your therapeutic development programs

Connect with a life sciences digital pathology expert today to explore how Proscia can help your organization tackle modern R&D’s biggest challenges.

Our website uses cookies. By using this site, you agree to its use of cookies.